A Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of Epcoritamab and Rituximab for Patients with Untreated Follicular Lymphoma (FL)

Protocol No
DFCI-22-702
Staff Member
Sumana Devata
Phase
II
Summary

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with FL and who have not received other treatments for their lymphoma
Objective
A phase 2 study of Epcoritamab and Rituximab for first-line treatment of follicular lymphoma.
Status
IRB INITIAL APPROVAL
Categories
Cancer, Lymphoma, Hematologic/Blood Related Cancers
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05783609